HOLLISTON, Mass., June 23, 2015 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, is set to simultaneously join two broad-market Russell indexes. According to Russell’s preliminary list of additions, the Company is expected to be added to the Russell 3000® Index and the Russell Global Index at the conclusion of the annual Russell indexes reconstitution on June 26, 2015.
Jeffrey A. Duchemin, President and Chief Executive Officer of Harvard Bioscience, said, “We believe inclusion in the Russell 3000 and Russell Global indexes will increase our recognition in the global financial community, much as our global commercial activities have enhanced our market position in the life sciences industry.”
Annual Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization. Membership in the Russell 3000 index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index as well as the appropriate growth and value style indexes. Membership in the Russell Global index, which also remains in place for one year, means automatic inclusion in the appropriate large-cap, small-cap, all-cap indexes as well as the applicable style, sector and country indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $5.7 trillion in assets are benchmarked to the Russell’s U.S. indexes. Russell indexes are part of FTSE Russell, a leading global index provider.
For more information on the Russell reconstitution, go to the “Recon Central” section on the FTSE Russell website.
About Harvard Bioscience
Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of solutions to advance life science. Our products are sold to thousands of researchers in over 100 countries through our global sales organization, websites, catalogs, and through distributors including Thermo Fisher Scientific Inc., VWR, GE Healthcare, and other specialized distributors. We have sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France, Canada and China. For more information, please visit our website at www.harvardbioscience.com.
The Harvard Bioscience logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=23828
About FTSE Russell
FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 80 countries, covering 98% of the investable market globally and trading on over 25 exchanges worldwide.
FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Leading asset owners, asset managers, ETF providers and investment banks use FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives.
A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance. FTSE Russell is also focused on index innovation and client collaboration as it seeks to enhance the breadth, depth and reach of its offering.
FTSE Russell is wholly owned by London Stock Exchange Group. For more information, visit www.ftserussell.com.
Safe Harbor Statement
Some of the statements in this press release are “forward-looking” and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These “forward-looking” statements include statements relating to, among other things, expectations regarding revenues and accretive earnings attributable to the acquisitions, statements or inferences about Harvard Bioscience’s or management’s beliefs or expectations, the company’s anticipated future revenues and earnings, the strength of the company’s market position and business model, the impact of acquisitions, the outlook for the life sciences industry, the company’s business strategy, the positioning of the company for growth, the market demand and opportunity for the company’s current products, or products it is developing or intends to develop, and the company’s plans, objectives and intentions that are not historical facts. These statements involve risks and uncertainties, including among other things, unanticipated costs relating to the acquisitions; the company’s failure to integrate the acquired businesses or technologies; the company’s inability to manage its growth; competition from the company’s competitors; technological changes resulting in the company’s products becoming obsolete; the company’s ability to retain key personnel; failure or inadequacy of the company’s information technology structure; and other factors that may cause the actual results to differ materially from the statements set forth in this press release. The forward-looking statements in this press release speak only as of the date of this press release. Harvard Bioscience expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.
For investor inquiries, please call (508) 893-8066. Press releases may be found on our web site.
CONTACT: Harvard Bioscience, Inc. Jeffrey A. Duchemin CEO and President jduchemin@harvardbioscience.com Robert E. Gagnon CFO rgagnon@harvardbioscience.com Tel: 508 893 8999 Fax: 508 429 8478 Investor Relations: Dian Griesel Int’l. Cheryl Schneider cschneider@dgicomm.com Public Relations: Susan Forman or Laura Radocaj sforman@dgicomm.com lradocaj@dgicomm.com
Help employers find you! Check out all the jobs and post your resume.
